The upregulation of OLFML2B increases the stromal scores by recruiting cancer-associated fibroblasts and other stromal cells, which have been proven to promote tumorigenesis, tumor angiogenesis, neoplasm metastasis, and drug resistance, especially in ESCA, KIRC, LIHC, STAD, and LGG. The gene discussed is OLFML2B; the disease is cancer.